TriangleBevacizumab (NCT05588388)
Bevacizumab trial for Extensive-stage Small-cell Lung Cancer (NCT05588388). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for people with extensive-stage small-cell lung cancer and liver metastases, without prior treatment for extensive-stage disease. Selected patients previously treated for limited-stage disease can qualify.
The idea: add bevacizumab, which blocks blood-vessel growth signals, to atezolizumab, carboplatin and etoposide. Atezolizumab blocks an immune checkpoint. Four three-week induction cycles are followed by atezolizumab and bevacizumab maintenance for up to one year, unless progression or toxicity stops treatment. Researchers assess safety and time without progression.
This phase 2 study plans 39 patients. Kamya Sankar leads three recruiting US sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.